{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T12:27:09Z","timestamp":1776342429286,"version":"3.51.2"},"reference-count":66,"publisher":"Portland Press Ltd.","issue":"23","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Background: With an increasing prevalence of obesity and metabolic syndrome, exploring the effects and delineating the mechanisms of possible therapeutic agents are of critical importance. We examined the effects of SGLT2 inhibitor-dapagliflozin on insulin resistance, hepatic gluconeogenesis, hepatic injury and pancreatic ER stress in high-fat diet-induced obese rats.<\/jats:p>\n               <jats:p>Materials and methods: Male Wistar rats were fed with normal diet (ND) or high-fat diet for 16 weeks. Then high-fat rats were given vehicle (HF) or dapagliflozin (1 mg\/kg\/day; HFDapa) or metformin (30 mg\/kg\/day; HFMet) for another 4 weeks.<\/jats:p>\n               <jats:p>Results: We found that dapagliflozin ameliorated high-fat diet-induced insulin resistance. The fasting plasma glucose level was comparable among groups, although dapagliflozin treatment led to substantial glycosuria. Hepatic gluconeogenic enzymes, PEPCK, G6Pase and FBPase, expression was not different in HF rats compared with ND rats. Meanwhile, dapagliflozin-treated group exhibited the elevation of these enzymes in parallel with the rise of transcription factor CREB, co-factor PGC1\u03b1 and upstream regulator SIRT1. Hepatic oxidative stress, inflammation and NAFLD activity score as well as hepatic and pancreatic ER stress and apoptosis in obese rats were attenuated by dapagliflozin.<\/jats:p>\n               <jats:p>Conclusion: We conclude that dapagliflozin improved obesity-related insulin resistance, hepatic and pancreatic injury independent of fasting plasma glucose level. Of note, dapagliflozin-induced glycosuria apparently triggered the up-regulation of hepatic gluconeogenic enzymes to prevent hypoglycemia.<\/jats:p>","DOI":"10.1042\/cs20190863","type":"journal-article","created":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T11:51:54Z","timestamp":1574769114000},"page":"2415-2430","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats"],"prefix":"10.1042","volume":"133","author":[{"given":"Myat\u00a0Theingi","family":"Swe","sequence":"first","affiliation":[{"name":"Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand"},{"name":"Department of Physiology, University of Medicine 2, Yangon, Myanmar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laongdao","family":"Thongnak","sequence":"additional","affiliation":[{"name":"Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krit","family":"Jaikumkao","sequence":"additional","affiliation":[{"name":"Department of Radiologic Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anchalee","family":"Pongchaidecha","sequence":"additional","affiliation":[{"name":"Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varanuj","family":"Chatsudthipong","sequence":"additional","affiliation":[{"name":"Research Center of Transport Protein for Medical Innovation, Faculty of Science, Mahidol University, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4522-0026","authenticated-orcid":false,"given":"Anusorn","family":"Lungkaphin","sequence":"additional","affiliation":[{"name":"Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand"},{"name":"Functional Food Research Center for Well-being, Chiang Mai University, Chiang Mai, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2019,12,10]]},"reference":[{"key":"2021113012333421400_B1","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.3390\/ijms20092358","article-title":"Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications","volume":"20","author":"Longo","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"2021113012333421400_B2","volume-title":"Insulin Resistance","author":"Freeman","year":"2019"},{"key":"2021113012333421400_B3","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/978-3-319-48382-5_12","article-title":"Insulin Resistance, Obesity and Lipotoxicity","volume":"960","author":"Yazici","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"2021113012333421400_B4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1365-2796.2006.01746.x","article-title":"Active sugar transport in health and disease","volume":"261","author":"Wright","year":"2007","journal-title":"J. Intern. Med."},{"key":"2021113012333421400_B5","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J. Clin. Invest."},{"key":"2021113012333421400_B6","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J. Clin. Invest."},{"key":"2021113012333421400_B7","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1111\/dom.13441","article-title":"Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats","volume":"20","author":"Jaikumkao","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"2021113012333421400_B8","first-page":"1881","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"Reply. N. Engl. J. Med."},{"key":"2021113012333421400_B9","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1210\/er.2010-0029","article-title":"Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes","volume":"32","author":"Abdul-Ghani","year":"2011","journal-title":"Endocr. Rev."},{"key":"2021113012333421400_B10","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1021\/jm701272q","article-title":"Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes","volume":"51","author":"Meng","year":"2008","journal-title":"J. Med. Chem."},{"key":"2021113012333421400_B11","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.2337\/dc10-0612","article-title":"Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"33","author":"Ferrannini","year":"2010","journal-title":"Diabetes Care"},{"key":"2021113012333421400_B12","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.2337\/dc11-0606","article-title":"Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial","volume":"34","author":"Nauck","year":"2011","journal-title":"Diabetes Care"},{"key":"2021113012333421400_B13","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/j.1463-1326.2011.01434.x","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial","volume":"13","author":"Strojek","year":"2011","journal-title":"Diabetes Obes. Metab."},{"key":"2021113012333421400_B14","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.2337\/dc09-0517","article-title":"A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment","volume":"32","author":"Wilding","year":"2009","journal-title":"Diabetes Care"},{"key":"2021113012333421400_B15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00125-008-1205-7","article-title":"Preventing hypoglycaemia: what is the appropriate glucose alert value?","volume":"52","author":"Cryer","year":"2009","journal-title":"Diabetologia"},{"key":"2021113012333421400_B16","doi-asserted-by":"publisher","first-page":"382","DOI":"10.2337\/diacare.24.2.382","article-title":"Renal gluconeogenesis: its importance in human glucose homeostasis","volume":"24","author":"Gerich","year":"2001","journal-title":"Diabetes Care."},{"key":"2021113012333421400_B17","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1146\/annurev.nu.11.070191.002341","article-title":"Hepatic gluconeogenesis\/glycolysis: regulation and structure\/function relationships of substrate cycle enzymes","volume":"11","author":"Pilkis","year":"1991","journal-title":"Annu. Rev. Nutr."},{"key":"2021113012333421400_B18","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2174\/156800805774912962","article-title":"Insulin regulation of PEPCK gene expression: a model for rapid and reversible modulation","volume":"5","author":"Quinn","year":"2005","journal-title":"Curr. Drug Targets Immune Endocr. Metabol. Disord."},{"key":"2021113012333421400_B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nut.2013.05.013","article-title":"Today\u2019s and yesterday\u2019s of pathophysiology: biochemistry of metabolic syndrome and animal models","volume":"30","author":"Aydin","year":"2014","journal-title":"Nutrition"},{"key":"2021113012333421400_B20","doi-asserted-by":"publisher","first-page":"351982","DOI":"10.1155\/2011\/351982","article-title":"Rodent models for metabolic syndrome research","volume":"2011","author":"Panchal","year":"2011","journal-title":"J. Biomed. Biotechnol."},{"key":"2021113012333421400_B21","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.lfs.2011.08.011","article-title":"Effects of estrogen in preventing neuronal insulin resistance in hippocampus of obese rats are different between genders","volume":"89","author":"Pratchayasakul","year":"2011","journal-title":"Life Sci."},{"key":"2021113012333421400_B22","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1016\/j.bbadis.2018.03.017","article-title":"Renal outcomes with sodium glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, in obese insulin-resistant model","volume":"1864","author":"Jaikumkao","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"2021113012333421400_B23","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3389\/fendo.2017.00326","article-title":"Saxagliptin Induces beta-Cell Proliferation through Increasing Stromal Cell-Derived Factor-1alpha In Vivo and In Vitro","volume":"8","author":"Li","year":"2017","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"2021113012333421400_B24","doi-asserted-by":"crossref","first-page":"394","DOI":"10.18632\/oncotarget.23037","article-title":"MnTBAP therapy attenuates the downregulation of sodium transporters in obstructive kidney disease","volume":"9","author":"Liu","year":"2018","journal-title":"Oncotarget"},{"key":"2021113012333421400_B25","doi-asserted-by":"publisher","first-page":"E952","DOI":"10.1152\/ajpendo.00314.2016","article-title":"Divergent functions of endotrophin on different cell populations in adipose tissue","volume":"311","author":"Zhao","year":"2016","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"2021113012333421400_B26","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"2021113012333421400_B27","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.2337\/db06-0391","article-title":"Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85alpha: the two sides of a coin","volume":"55","author":"Draznin","year":"2006","journal-title":"Diabetes"},{"key":"2021113012333421400_B28","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s13679-017-0261-z","article-title":"Hyperinsulinemia: a Cause of Obesity?","volume":"6","author":"Erion","year":"2017","journal-title":"Curr. Obes. Rep."},{"key":"2021113012333421400_B29","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1172\/JCI117864","article-title":"Skeletal muscle utilization of free fatty acids in women with visceral obesity","volume":"95","author":"Colberg","year":"1995","journal-title":"J. Clin. Invest."},{"key":"2021113012333421400_B30","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.2337\/diabetes.50.11.2548","article-title":"Plasma free Fatty Acid uptake and oxidation are already diminished in subjects at high risk for developing type 2 diabetes","volume":"50","author":"Mensink","year":"2001","journal-title":"Diabetes"},{"key":"2021113012333421400_B31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2017.04.011","article-title":"Sodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology","volume":"26","author":"Ferrannini","year":"2017","journal-title":"Cell Metab."},{"key":"2021113012333421400_B32","first-page":"463","article-title":"Glucose counterregulatory responses to hypoglycemia","volume":"9","author":"Sprague","year":"2011","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"2021113012333421400_B33","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1053\/meta.2002.34700","article-title":"Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals","volume":"51","author":"Matsuda","year":"2002","journal-title":"Metabolism"},{"key":"2021113012333421400_B34","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","author":"Bonner","year":"2015","journal-title":"Nat. Med."},{"key":"2021113012333421400_B35","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41467-018-08193-8","article-title":"Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion","volume":"10","author":"Vergari","year":"2019","journal-title":"Nat. Commun."},{"key":"2021113012333421400_B36","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s00125-006-0511-1","article-title":"Glucose inhibits glucagon secretion by a direct effect on mouse pancreatic alpha cells","volume":"50","author":"Vieira","year":"2007","journal-title":"Diabetologia"},{"key":"2021113012333421400_B37","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nrm3072","article-title":"CREB and the CRTC co-activators: sensors for hormonal and metabolic signals","volume":"12","author":"Altarejos","year":"2011","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2021113012333421400_B38","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/35093131","article-title":"CREB regulates hepatic gluconeogenesis through the coactivator PGC-1","volume":"413","author":"Herzig","year":"2001","journal-title":"Nature"},{"key":"2021113012333421400_B39","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.2337\/db07-0480","article-title":"Hepatic lipin 1beta expression is diminished in insulin-resistant obese subjects and is reactivated by marked weight loss","volume":"56","author":"Croce","year":"2007","journal-title":"Diabetes"},{"key":"2021113012333421400_B40","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1126\/science.273.5277.959","article-title":"Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase","volume":"273","author":"Xing","year":"1996","journal-title":"Science"},{"key":"2021113012333421400_B41","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.2337\/db07-0714","article-title":"Increased expression and activity of the transcription factor FOXO1 in nonalcoholic steatohepatitis","volume":"57","author":"Valenti","year":"2008","journal-title":"Diabetes"},{"key":"2021113012333421400_B42","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0002-9343(81)90422-8","article-title":"Mechanisms of insulin resistance in obesity and noninsulin-dependent (type II) diabetes","volume":"70","author":"Olefsky","year":"1981","journal-title":"Am. J. Med."},{"key":"2021113012333421400_B43","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1210\/en.2015-1588","article-title":"Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice","volume":"157","author":"Obata","year":"2016","journal-title":"Endocrinology"},{"key":"2021113012333421400_B44","doi-asserted-by":"publisher","first-page":"852","DOI":"10.7150\/ijbs.19370","article-title":"Emerging roles of SIRT1 in fatty liver diseases","volume":"13","author":"Ding","year":"2017","journal-title":"Int. J. Biol. Sci."},{"key":"2021113012333421400_B45","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1126\/science.1099196","article-title":"Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase","volume":"305","author":"Cohen","year":"2004","journal-title":"Science"},{"key":"2021113012333421400_B46","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/j.1478-3231.2007.01497.x","article-title":"The expression of SIRT1 in nonalcoholic fatty liver disease induced by high-fat diet in rats","volume":"27","author":"Deng","year":"2007","journal-title":"Liver Int."},{"key":"2021113012333421400_B47","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.molmet.2013.10.006","article-title":"SIRT1 metabolic actions: Integrating recent advances from mouse models","volume":"3","author":"Boutant","year":"2014","journal-title":"Mol. Metab."},{"key":"2021113012333421400_B48","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature05354","article-title":"Resveratrol improves health and survival of mice on a high-calorie diet","volume":"444","author":"Baur","year":"2006","journal-title":"Nature"},{"key":"2021113012333421400_B49","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.cmet.2006.04.013","article-title":"GCN5 acetyltransferase complex controls glucose metabolism through transcriptional repression of PGC-1alpha","volume":"3","author":"Lerin","year":"2006","journal-title":"Cell Metab."},{"key":"2021113012333421400_B50","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature03354","article-title":"Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1","volume":"434","author":"Rodgers","year":"2005","journal-title":"Nature"},{"key":"2021113012333421400_B51","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1042\/BJ20120546","article-title":"AMP-activated protein kinase: new regulation, new roles?","volume":"445","author":"Carling","year":"2012","journal-title":"Biochem J."},{"key":"2021113012333421400_B52","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19103092","article-title":"Nutritional Modulation of AMPK-Impact upon Metabolic-Inflammation","volume":"19","author":"Lyons","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"2021113012333421400_B53","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/nature07813","article-title":"AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity","volume":"458","author":"Canto","year":"2009","journal-title":"Nature"},{"key":"2021113012333421400_B54","doi-asserted-by":"publisher","first-page":"12017","DOI":"10.1073\/pnas.0705070104","article-title":"AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha","volume":"104","author":"Jager","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113012333421400_B55","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.1038\/emm.2016.81","article-title":"Regulation and function of AMPK in physiology and diseases","volume":"48","author":"Jeon","year":"2016","journal-title":"Exp. Mol. Med."},{"key":"2021113012333421400_B56","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/MCO.0000000000000380","article-title":"AMP-activated protein kinase, fatty acid metabolism, and insulin sensitivity","volume":"20","author":"Smith","year":"2017","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"2021113012333421400_B57","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1113\/jphysiol.2007.135871","article-title":"Diabetes associated cell stress and dysfunction: role of mitochondrial and non-mitochondrial ROS production and activity","volume":"583","author":"Newsholme","year":"2007","journal-title":"J. Physiol."},{"key":"2021113012333421400_B58","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1758-5996-3-17","article-title":"Biochemical study of oxidative stress markers in the liver, kidney and heart of high fat diet induced obesity in rats","volume":"3","author":"Noeman","year":"2011","journal-title":"Diabetol. Metab. Syndr."},{"key":"2021113012333421400_B59","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.exger.2009.07.003","article-title":"Roles of the lipid peroxidation product 4-hydroxynonenal in obesity, the metabolic syndrome, and associated vascular and neurodegenerative disorders","volume":"44","author":"Mattson","year":"2009","journal-title":"Exp. Gerontol."},{"key":"2021113012333421400_B60","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S0261-5614(99)80015-6","article-title":"Non-alcoholic fatty liver: another feature of the metabolic syndrome?","volume":"18","author":"Cortez-Pinto","year":"1999","journal-title":"Clin. Nutr."},{"key":"2021113012333421400_B61","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jceh.2015.02.005","article-title":"Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice","volume":"5","author":"Nakano","year":"2015","journal-title":"J. Clin. Exp. Hepatol."},{"key":"2021113012333421400_B62","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"2021113012333421400_B63","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3892\/br.2012.18","article-title":"Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"1","author":"Li","year":"2013","journal-title":"Biomed. Rep."},{"key":"2021113012333421400_B64","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1126\/science.1103160","article-title":"Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes","volume":"306","author":"Ozcan","year":"2004","journal-title":"Science"},{"key":"2021113012333421400_B65","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1210\/endo.143.2.8623","article-title":"Minireview: Secondary beta-cell failure in type 2 diabetes\u2013a convergence of glucotoxicity and lipotoxicity","volume":"143","author":"Poitout","year":"2002","journal-title":"Endocrinology"},{"key":"2021113012333421400_B66","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1210\/er.2007-0039","article-title":"The unfolded protein response: a pathway that links insulin demand with beta-cell failure and diabetes","volume":"29","author":"Scheuner","year":"2008","journal-title":"Endocr. Rev."}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/133\/23\/2415\/862629\/cs-2019-0863.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/133\/23\/2415\/862629\/cs-2019-0863.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T12:34:03Z","timestamp":1638275643000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/133\/23\/2415\/221335\/Dapagliflozin-not-only-improves-hepatic-injury-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":66,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2019,12,12]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20190863","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,12]]},"published":{"date-parts":[[2019,12]]}}}